section name header

Indications

High Alert


Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Derm: alopecia

GI: diarrhea, nausea, vomiting, abdominal pain

Hemat: AGRANULOCYTOSIS, APLASTIC ANEMIA, leukopenia, thrombocytopenia

MS: myalgia, RHABDOMYOLYSIS

Neuro: peripheral neuritis

Interactions

Drug-drug:

Drug-Food:

Availability

(Generic available)

Route/Dosage

Treatment of Gout Flares (Colcrys and Generic Tablets Only)

Renal Impairment

Prevention of Gout Flares (Gloperba, Mitigare, and Generic Capsules Only)

Renal Impairment

Familial Mediterranean Fever (Colcrys and Generic Tablets Only)

Renal Impairment

Reduction in Risk of MI, Stroke, Coronary Revascularization, and Cardiovascular Death

US Brand Names

Colcrys, Gloperba, Lodoco, Mitigare

Action

  • Interferes with the functions of WBCs in initiating and perpetuating the inflammatory response to monosodium urate crystals.
Therapeutic effects:
  • Decreased pain and inflammation in acute attacks of gout.
  • Reduced number of attacks of gout and familial Mediterranean fever.
  • Reduction in risk of MI, stroke, coronary revascularization, and cardiovascular death in patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease.

Classifications

Therapeutic Classification: antigout agents

Pharmacokinetics

Absorption: 45% absorbed from the GI tract, then re-enters GI tract from biliary secretions, when more absorption may occur.

Distribution: Extensively distributed to tissues.

Metabolism/Excretion: Partially metabolized by the liver by the CYP3A4 isoenzyme; also a substrate for P-glycoprotein. Secreted in bile back into GI tract; eliminated in the feces. 40–65% excreted in the urine as unchanged drug.

Half-Life: 19–31 hr.

Time/Action Profile

(anti-inflammatory activity)

ROUTEONSETPEAKDURATION
PO12 hr24–72 hrunknown



Patient/Family Teaching

Pronunciation

KOL-chi-seen